OncoMed Pharmaceuticals, Inc. reported unaudited earning results for the quarter and year ended December 31, 2017. For the quarter, total revenue was $20,640,000 compared to $6,219,000 a year ago. Income from operations was $8,245,000 compared to loss of $22,389,000 a year ago. Income before provision for income taxes was $8,368,000 compared to loss of $22,336,000 a year ago. Net income was $9,463,000 or $0.25 per basic and diluted share compared to loss of $22,334,000 or $0.6 per basic and diluted share a year ago. For the year, total revenue was $38,154,000 compared to $25,153,000 a year ago. Loss from operations was $40,973,000 compared to loss of $103,387,000 a year ago. Loss before provision for income taxes was $40,145,000 compared to loss of $103,088,000 a year ago. Net loss was $39,062,000 or $1.04 per basic and diluted share compared to loss of $103,102,000 or $3.14 per basic and diluted share a year ago.